Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Quimioterapia combinada, bevacizumab y/o atezolizumab en el tratamiento de pacientes con cáncer colorrectal metastásico en la reparación de errores de emparejamiento de ADN deficiente, el estudio COMMIT

11 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Estudio de inmunoterapia (COMMIT) con dMMR/MSI-H metastásico para el cáncer colorrectal: un estudio aleatorizado de fase III de la combinación de mFOLFOX6/bevacizumab/atezolizumab frente al agente único atezolizumab en el tratamiento de primera línea de pacientes con reparación deficiente de errores de emparejamiento del ADN (dMMR)/microsatélite Inestabilidad alta (MSI-H) Cáncer colorrectal metastásico

This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVE:

I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.

SECONDARY OBJECTIVES:

I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).

IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.

TRANSLATIONAL OBJECTIVE:

I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Kingman, Arizona, Estados Unidos, 86401
        • Kingman Regional Medical Center
    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Anaheim, California, Estados Unidos, 92806
        • Kaiser Permanente-Anaheim
      • Baldwin Park, California, Estados Unidos, 91706
        • Kaiser Permanente-Baldwin Park
      • Bellflower, California, Estados Unidos, 90706
        • Kaiser Permanente-Bellflower
      • Berkeley, California, Estados Unidos, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Concord, California, Estados Unidos, 94520
        • John Muir Medical Center-Concord
      • Fontana, California, Estados Unidos, 92335
        • Kaiser Permanente-Fontana
      • Harbor City, California, Estados Unidos, 90710
        • Kaiser Permanente South Bay
      • Irvine, California, Estados Unidos, 92618
        • Kaiser Permanente-Irvine
      • Los Angeles, California, Estados Unidos, 90027
        • Kaiser Permanente Los Angeles Medical Center
      • Los Angeles, California, Estados Unidos, 90034
        • Kaiser Permanente West Los Angeles
      • Marysville, California, Estados Unidos, 95901
        • Fremont - Rideout Cancer Center
      • Modesto, California, Estados Unidos, 95355
        • Memorial Medical Center
      • Ontario, California, Estados Unidos, 91761
        • Kaiser Permanente-Ontario
      • Orange, California, Estados Unidos, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Orange, California, Estados Unidos, 92868
        • Saint Joseph Hospital - Orange
      • Panorama City, California, Estados Unidos, 91402
        • Kaiser Permanente - Panorama City
      • Riverside, California, Estados Unidos, 92505
        • Kaiser Permanente-Riverside
      • Sacramento, California, Estados Unidos, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, Estados Unidos, 95817
        • University of California Davis Comprehensive Cancer Center
      • Salinas, California, Estados Unidos, 93901
        • Salinas Valley Memorial
      • San Diego, California, Estados Unidos, 92120
        • Kaiser Permanente-San Diego Zion
      • San Diego, California, Estados Unidos, 92108
        • Kaiser Permanente-Rio San Diego
      • San Marcos, California, Estados Unidos, 92078
        • Kaiser Permanente-San Marcos
      • Walnut Creek, California, Estados Unidos, 94598
        • John Muir Medical Center-Walnut Creek
      • Whittier, California, Estados Unidos, 90602
        • Presbyterian Intercommunity Hospital
      • Woodland Hills, California, Estados Unidos, 91367
        • Kaiser Permanente-Woodland Hills
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • Rocky Mountain Cancer Centers-Aurora
      • Aurora, Colorado, Estados Unidos, 80045
        • UCHealth University of Colorado Hospital
      • Boulder, Colorado, Estados Unidos, 80303
        • Boulder Community Foothills Hospital
      • Boulder, Colorado, Estados Unidos, 80304
        • Rocky Mountain Cancer Centers-Boulder
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Penrose-Saint Francis Healthcare
      • Colorado Springs, Colorado, Estados Unidos, 80909
        • UCHealth Memorial Hospital Central
      • Colorado Springs, Colorado, Estados Unidos, 80920
        • Memorial Hospital North
      • Denver, Colorado, Estados Unidos, 80218
        • Rocky Mountain Cancer Centers-Midtown
      • Denver, Colorado, Estados Unidos, 80220
        • Rocky Mountain Cancer Centers-Rose
      • Denver, Colorado, Estados Unidos, 80204
        • Denver Health Medical Center
      • Denver, Colorado, Estados Unidos, 80206
        • National Jewish Health-Main Campus
      • Denver, Colorado, Estados Unidos, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, Estados Unidos, 80210
        • AdventHealth Porter
      • Englewood, Colorado, Estados Unidos, 80113
        • Mountain Blue Cancer Care Center - Swedish
      • Englewood, Colorado, Estados Unidos, 80113
        • Swedish Medical Center
      • Fort Collins, Colorado, Estados Unidos, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, Estados Unidos, 80528
        • Cancer Care and Hematology-Fort Collins
      • Golden, Colorado, Estados Unidos, 80401
        • National Jewish Health-Western Hematology Oncology
      • Greeley, Colorado, Estados Unidos, 80631
        • UCHealth Greeley Hospital
      • Greeley, Colorado, Estados Unidos, 80631
        • Banner North Colorado Medical Center
      • Littleton, Colorado, Estados Unidos, 80120
        • Rocky Mountain Cancer Centers-Littleton
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Rocky Mountain Cancer Centers-Sky Ridge
      • Loveland, Colorado, Estados Unidos, 80538
        • Medical Center of the Rockies
      • Loveland, Colorado, Estados Unidos, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Thornton, Colorado, Estados Unidos, 80260
        • National Jewish Health-Northern Hematology Oncology
      • Wheat Ridge, Colorado, Estados Unidos, 80401
        • Intermountain Health Lutheran Hospital
    • Connecticut
      • Danbury, Connecticut, Estados Unidos, 06810
        • Danbury Hospital
      • Hartford, Connecticut, Estados Unidos, 06102
        • Hartford Hospital
      • Meriden, Connecticut, Estados Unidos, 06451
        • Midstate Medical Center
      • New Britain, Connecticut, Estados Unidos, 06050
        • The Hospital of Central Connecticut
      • Norwich, Connecticut, Estados Unidos, 06360
        • William Backus Hospital
    • Delaware
      • Millville, Delaware, Estados Unidos, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, Estados Unidos, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Estados Unidos, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, Estados Unidos, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20002
        • Kaiser Permanente-Capitol Hill Medical Center
    • Florida
      • Fort Lauderdale, Florida, Estados Unidos, 33316
        • Broward Health Medical Center
      • Fort Myers, Florida, Estados Unidos, 33905
        • Regional Cancer Center-Lee Memorial Health System
      • Gainesville, Florida, Estados Unidos, 32610
        • UF Health Cancer Institute - Gainesville
      • Jacksonville, Florida, Estados Unidos, 32207
        • Baptist MD Anderson Cancer Center
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando
    • Georgia
      • Albany, Georgia, Estados Unidos, 31701
        • Phoebe Putney Memorial Hospital
      • Athens, Georgia, Estados Unidos, 30607
        • University Cancer and Blood Center LLC
      • Augusta, Georgia, Estados Unidos, 30912
        • Augusta University Medical Center
      • Augusta, Georgia, Estados Unidos, 30901
        • Augusta Oncology Associates PC-D'Antignac
      • Augusta, Georgia, Estados Unidos, 30909
        • Augusta Oncology Associates PC-Wheeler
      • Newnan, Georgia, Estados Unidos, 30265
        • CTCA at Southeastern Regional Medical Center
    • Idaho
      • Boise, Idaho, Estados Unidos, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Estados Unidos, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Estados Unidos, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Estados Unidos, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Estados Unidos, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Estados Unidos, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Estados Unidos, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Estados Unidos, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Estados Unidos, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Estados Unidos, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Bloomington, Illinois, Estados Unidos, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, Estados Unidos, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, Estados Unidos, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, Estados Unidos, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Estados Unidos, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Estados Unidos, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, Estados Unidos, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, Estados Unidos, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Estados Unidos, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, Estados Unidos, 61530
        • Illinois CancerCare-Eureka
      • Evanston, Illinois, Estados Unidos, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Illinois CancerCare-Galesburg
      • Glenview, Illinois, Estados Unidos, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park, Illinois, Estados Unidos, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Kewanee, Illinois, Estados Unidos, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Estados Unidos, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, Estados Unidos, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Maywood, Illinois, Estados Unidos, 60153
        • Loyola University Medical Center
      • Mount Vernon, Illinois, Estados Unidos, 62864
        • SSM Health Good Samaritan
      • O'Fallon, Illinois, Estados Unidos, 62269
        • Cancer Care Center of O'Fallon
      • Ottawa, Illinois, Estados Unidos, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, Estados Unidos, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, Estados Unidos, 61356
        • Illinois CancerCare-Princeton
      • Springfield, Illinois, Estados Unidos, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Estados Unidos, 62702
        • Springfield Clinic
      • Urbana, Illinois, Estados Unidos, 61801
        • Carle Cancer Center
      • Washington, Illinois, Estados Unidos, 61571
        • Illinois CancerCare - Washington
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46237
        • Franciscan Health Indianapolis
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Estados Unidos, 46219
        • Community Cancer Center East
      • Indianapolis, Indiana, Estados Unidos, 46227
        • Community Cancer Center South
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Community Cancer Center North
      • Kokomo, Indiana, Estados Unidos, 46904
        • Community Howard Regional Health
      • Lafayette, Indiana, Estados Unidos, 47905
        • Franciscan Saint Elizabeth Health - Lafayette East
      • Michigan City, Indiana, Estados Unidos, 46360
        • Woodland Cancer Care Center
      • Mooresville, Indiana, Estados Unidos, 46158
        • Franciscan Health Mooresville
      • Terre Haute, Indiana, Estados Unidos, 47804
        • Union Hospital
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Estados Unidos, 50010
        • McFarland Clinic - Ames
      • Bettendorf, Iowa, Estados Unidos, 52722
        • University of Iowa Healthcare Cancer Services Quad Cities
      • Boone, Iowa, Estados Unidos, 50036
        • McFarland Clinic - Boone
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Estados Unidos, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Estados Unidos, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50314
        • Broadlawns Medical Center
      • Des Moines, Iowa, Estados Unidos, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Estados Unidos, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Fort Dodge, Iowa, Estados Unidos, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Fort Dodge, Iowa, Estados Unidos, 50501
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Estados Unidos, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Estados Unidos, 50158
        • McFarland Clinic - Marshalltown
      • West Des Moines, Iowa, Estados Unidos, 50266
        • Mercy Medical Center-West Lakes
    • Kansas
      • Hays, Kansas, Estados Unidos, 67601
        • HaysMed
      • Lawrence, Kansas, Estados Unidos, 66044
        • Lawrence Memorial Hospital
      • Olathe, Kansas, Estados Unidos, 66061
        • The University of Kansas Cancer Center - Olathe
      • Salina, Kansas, Estados Unidos, 67401
        • Salina Regional Health Center
      • Topeka, Kansas, Estados Unidos, 66606
        • University of Kansas Health System Saint Francis Campus
      • Westwood, Kansas, Estados Unidos, 66205
        • University of Kansas Hospital-Westwood Cancer Center
      • Wichita, Kansas, Estados Unidos, 67208
        • Cancer Center of Kansas-Wichita Medical Arts Tower
      • Wichita, Kansas, Estados Unidos, 67214
        • Cancer Center of Kansas - Wichita
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • CommonSpirit Saint Joseph Hospital - Bardstown
      • Lexington, Kentucky, Estados Unidos, 40536
        • University of Kentucky/Markey Cancer Center
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Lexington
      • Lexington, Kentucky, Estados Unidos, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • Louisville, Kentucky, Estados Unidos, 40202
        • Norton Hospital Pavilion and Medical Campus
      • Louisville, Kentucky, Estados Unidos, 40241
        • Norton Brownsboro Hospital and Medical Campus
      • Louisville, Kentucky, Estados Unidos, 40217
        • Norton Audubon Hospital and Medical Campus
    • Louisiana
      • Kenner, Louisiana, Estados Unidos, 70065
        • Ochsner Medical Center Kenner
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Augusta, Maine, Estados Unidos, 04330
        • Harold Alfond Center for Cancer Care
      • Bangor, Maine, Estados Unidos, 04401
        • Eastern Maine Medical Center
      • Belfast, Maine, Estados Unidos, 04915
        • MaineHealth Waldo Hospital
      • Biddeford, Maine, Estados Unidos, 04005
        • MaineHealth Maine Medical Center - Biddeford
      • Brewer, Maine, Estados Unidos, 04412
        • Lafayette Family Cancer Center-EMMC
      • Rockport, Maine, Estados Unidos, 04856
        • Penobscot Bay Medical Center
      • Sanford, Maine, Estados Unidos, 04073
        • MaineHealth Cancer Care and IV Therapy - Sanford
      • South Portland, Maine, Estados Unidos, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21244
        • Kaiser Permanente-Woodlawn Medical Center
      • Easton, Maryland, Estados Unidos, 21601
        • University of Maryland Shore Medical Center at Easton
      • Gaithersburg, Maryland, Estados Unidos, 20879
        • Kaiser Permanente-Gaithersburg Medical Center
      • Largo, Maryland, Estados Unidos, 20774
        • Kaiser Permanente - Largo Medical Center
      • Lutherville, Maryland, Estados Unidos, 21093
        • Kaiser Permanente Lutherville - Timonium Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Dana-Farber Cancer Institute
      • Lowell, Massachusetts, Estados Unidos, 01854
        • Lowell General Hospital
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Bay City, Michigan, Estados Unidos, 48706
        • McLaren Cancer Institute-Bay City
      • Bloomfield, Michigan, Estados Unidos, 48302
        • McLaren Cancer Institute-Bloomfield
      • Brighton, Michigan, Estados Unidos, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton, Michigan, Estados Unidos, 48114
        • Trinity Health Medical Center - Brighton
      • Brownstown, Michigan, Estados Unidos, 48183
        • Henry Ford Cancer Institute-Downriver
      • Canton, Michigan, Estados Unidos, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton, Michigan, Estados Unidos, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, Estados Unidos, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea, Michigan, Estados Unidos, 48118
        • Chelsea Hospital
      • Clarkston, Michigan, Estados Unidos, 48346
        • McLaren Cancer Institute-Clarkston
      • Clarkston, Michigan, Estados Unidos, 48346
        • Hematology Oncology Consultants-Clarkston
      • Clarkston, Michigan, Estados Unidos, 48346
        • Newland Medical Associates-Clarkston
      • Clinton Township, Michigan, Estados Unidos, 48038
        • Henry Ford Macomb Hospital-Clinton Township
      • Dearborn, Michigan, Estados Unidos, 48126
        • Henry Ford Medical Center-Fairlane
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Hospital
      • Detroit, Michigan, Estados Unidos, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Weisberg Cancer Treatment Center
      • Flint, Michigan, Estados Unidos, 48532
        • McLaren Cancer Institute-Flint
      • Flint, Michigan, Estados Unidos, 48532
        • Singh and Arora Hematology Oncology PC
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Jackson, Michigan, Estados Unidos, 49201
        • Allegiance Health
      • Kalamazoo, Michigan, Estados Unidos, 49007
        • West Michigan Cancer Center
      • Lansing, Michigan, Estados Unidos, 48910
        • Karmanos Cancer Institute at McLaren Greater Lansing
      • Lansing, Michigan, Estados Unidos, 48912
        • University of Michigan Health - Sparrow Lansing
      • Lapeer, Michigan, Estados Unidos, 48446
        • McLaren Cancer Institute-Lapeer Region
      • Livonia, Michigan, Estados Unidos, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Livonia, Michigan, Estados Unidos, 48154
        • Hope Cancer Clinic
      • Mount Clemens, Michigan, Estados Unidos, 48043
        • McLaren Cancer Institute-Macomb
      • Mount Pleasant, Michigan, Estados Unidos, 48858
        • McLaren Cancer Institute-Central Michigan
      • Novi, Michigan, Estados Unidos, 48377
        • Henry Ford Medical Center-Columbus
      • Petoskey, Michigan, Estados Unidos, 49770
        • McLaren Cancer Institute-Northern Michigan
      • Pontiac, Michigan, Estados Unidos, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Pontiac, Michigan, Estados Unidos, 48341
        • Trinity Health IHA Medical Group-Alice Gustafson Center
      • Port Huron, Michigan, Estados Unidos, 48060
        • McLaren-Port Huron
      • Saginaw, Michigan, Estados Unidos, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Estados Unidos, 48601
        • MyMichigan Medical Center Saginaw
      • Tawas City, Michigan, Estados Unidos, 48764
        • MyMichigan Medical Center Tawas
      • Traverse City, Michigan, Estados Unidos, 49684
        • Munson Medical Center
      • West Bloomfield, Michigan, Estados Unidos, 48322
        • Henry Ford West Bloomfield Hospital
      • West Branch, Michigan, Estados Unidos, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, Estados Unidos, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Bemidji, Minnesota, Estados Unidos, 56601
        • Sanford Joe Lueken Cancer Center
      • Burnsville, Minnesota, Estados Unidos, 55337
        • Minnesota Oncology - Burnsville
      • Deer River, Minnesota, Estados Unidos, 56636
        • Essentia Health - Deer River Clinic
      • Duluth, Minnesota, Estados Unidos, 55805
        • Essentia Health Cancer Center
      • Hibbing, Minnesota, Estados Unidos, 55746
        • Essentia Health Hibbing Clinic
      • Maplewood, Minnesota, Estados Unidos, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Estados Unidos, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Estados Unidos, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Estados Unidos, 55454
        • Health Partners Inc
      • Saint Paul, Minnesota, Estados Unidos, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Estados Unidos, 55102
        • United Hospital
      • Sandstone, Minnesota, Estados Unidos, 55072
        • Essentia Health Sandstone
      • Virginia, Minnesota, Estados Unidos, 55792
        • Essentia Health Virginia Clinic
    • Mississippi
      • Grenada, Mississippi, Estados Unidos, 38901
        • Baptist Cancer Center-Grenada
      • New Albany, Mississippi, Estados Unidos, 38652
        • Baptist Memorial Hospital and Cancer Center-Union County
      • Oxford, Mississippi, Estados Unidos, 38655
        • Baptist Memorial Hospital and Cancer Center-Oxford
      • Southhaven, Mississippi, Estados Unidos, 38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Ballwin, Missouri, Estados Unidos, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Saint Francis Medical Center
      • Columbia, Missouri, Estados Unidos, 65212
        • MU Health - University Hospital/Ellis Fischel Cancer Center
      • Joplin, Missouri, Estados Unidos, 64804
        • Freeman Health System
      • Joplin, Missouri, Estados Unidos, 64804
        • Mercy Hospital Joplin
      • Kansas City, Missouri, Estados Unidos, 64108
        • University Health Truman Medical Center
      • St Louis, Missouri, Estados Unidos, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
    • Montana
      • Anaconda, Montana, Estados Unidos, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Estados Unidos, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Benefis Sletten Cancer Institute
      • Helena, Montana, Estados Unidos, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Estados Unidos, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Estados Unidos, 59804
        • Community Medical Center
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Estados Unidos, 89128
        • OptumCare Cancer Care at MountainView
      • Las Vegas, Nevada, Estados Unidos, 89183
        • OptumCare Cancer Care at Fort Apache
      • Reno, Nevada, Estados Unidos, 89502
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
      • Manchester, New Hampshire, Estados Unidos, 03104
        • Dartmouth Cancer Center - Manchester/ DCC Manchester
      • Nashua, New Hampshire, Estados Unidos, 03063
        • Dartmouth Cancer Center - Nashua
    • New Jersey
      • Hamilton, New Jersey, Estados Unidos, 08690
        • The Cancer Institute of New Jersey Hamilton
      • Morristown, New Jersey, Estados Unidos, 07960
        • Morristown Medical Center
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey
      • Paramus, New Jersey, Estados Unidos, 07652
        • The Valley Hospital - Luckow Pavilion
      • Ridgewood, New Jersey, Estados Unidos, 07450
        • Valley Health System Ridgewood Campus
      • Somerville, New Jersey, Estados Unidos, 08876
        • Robert Wood Johnson University Hospital Somerset
      • Summit, New Jersey, Estados Unidos, 07902
        • Overlook Hospital
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • University of New Mexico Cancer Center
      • Albuquerque, New Mexico, Estados Unidos, 87110
        • Presbyterian Kaseman Hospital
      • Las Cruces, New Mexico, Estados Unidos, 88011
        • Memorial Medical Center-Las Cruces
      • Rio Rancho, New Mexico, Estados Unidos, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute
      • Elmira, New York, Estados Unidos, 14905
        • Arnot Ogden Medical Center/Falck Cancer Center
      • Lake Success, New York, Estados Unidos, 11042
        • Northwell Health/Center for Advanced Medicine
      • New York, New York, Estados Unidos, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, Estados Unidos, 14642
        • University of Rochester
      • White Plains, New York, Estados Unidos, 10601
        • Dickstein Cancer Treatment Center
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Clinton, North Carolina, Estados Unidos, 28328
        • Southeastern Medical Oncology Center-Clinton
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Southeastern Medical Oncology Center-Goldsboro
      • Hendersonville, North Carolina, Estados Unidos, 28791
        • Margaret R Pardee Memorial Hospital
      • Jacksonville, North Carolina, Estados Unidos, 28546
        • Southeastern Medical Oncology Center-Jacksonville
      • Kenansville, North Carolina, Estados Unidos, 28349
        • ECU Health Oncology Kenansville
      • Kinston, North Carolina, Estados Unidos, 28501
        • ECU Health Oncology Kinston
      • Pinehurst, North Carolina, Estados Unidos, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
      • Richlands, North Carolina, Estados Unidos, 28574
        • ECU Health Oncology Richlands
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, Estados Unidos, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Estados Unidos, 58122
        • Sanford Broadway Medical Center
      • Grand Forks, North Dakota, Estados Unidos, 58201
        • Altru Cancer Center
    • Ohio
      • Akron, Ohio, Estados Unidos, 44307
        • Cleveland Clinic Akron General
      • Belpre, Ohio, Estados Unidos, 45714
        • Strecker Cancer Center-Belpre
      • Centerville, Ohio, Estados Unidos, 45459
        • Miami Valley Hospital South
      • Centerville, Ohio, Estados Unidos, 45459
        • Dayton Physicians LLC-Miami Valley South
      • Chillicothe, Ohio, Estados Unidos, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cleveland, Ohio, Estados Unidos, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Estados Unidos, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Estados Unidos, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Estados Unidos, 43214
        • Columbus Oncology and Hematology Associates Inc
      • Columbus, Ohio, Estados Unidos, 43228
        • Doctors Hospital
      • Columbus, Ohio, Estados Unidos, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Estados Unidos, 43215
        • Grant Medical Center
      • Columbus, Ohio, Estados Unidos, 43222
        • Mount Carmel Health Center West
      • Dayton, Ohio, Estados Unidos, 45409
        • Miami Valley Hospital
      • Delaware, Ohio, Estados Unidos, 43015
        • Delaware Health Center-Grady Cancer Center
      • Delaware, Ohio, Estados Unidos, 43015
        • Grady Memorial Hospital
      • Kettering, Ohio, Estados Unidos, 45409
        • Greater Dayton Cancer Center
      • Lancaster, Ohio, Estados Unidos, 43130
        • Fairfield Medical Center
      • Mansfield, Ohio, Estados Unidos, 44906
        • Cleveland Clinic Cancer Center Mansfield
      • Mansfield, Ohio, Estados Unidos, 44903
        • OhioHealth Mansfield Hospital
      • Marietta, Ohio, Estados Unidos, 45750
        • Marietta Memorial Hospital
      • Marion, Ohio, Estados Unidos, 43302
        • OhioHealth Marion General Hospital
      • Mayfield Heights, Ohio, Estados Unidos, 44124
        • Hillcrest Hospital Cancer Center
      • Mount Vernon, Ohio, Estados Unidos, 43050
        • Knox Community Hospital
      • Newark, Ohio, Estados Unidos, 43055
        • Licking Memorial Hospital
      • Portsmouth, Ohio, Estados Unidos, 45662
        • Southern Ohio Medical Center
      • Sandusky, Ohio, Estados Unidos, 44870
        • North Coast Cancer Care
      • Sylvania, Ohio, Estados Unidos, 43560
        • ProMedica Flower Hospital
      • Warrensville Heights, Ohio, Estados Unidos, 44122
        • South Pointe Hospital
      • West Chester, Ohio, Estados Unidos, 45069
        • University of Cincinnati Cancer Center-West Chester
      • Westerville, Ohio, Estados Unidos, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, Estados Unidos, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Lawton, Oklahoma, Estados Unidos, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, Estados Unidos, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
      • Tulsa, Oklahoma, Estados Unidos, 74133
        • Cancer Treatment Centers of America
    • Oregon
      • Bend, Oregon, Estados Unidos, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, Estados Unidos, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, Estados Unidos, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Newberg, Oregon, Estados Unidos, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Estados Unidos, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Oregon City, Oregon, Estados Unidos, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, Estados Unidos, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Estados Unidos, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Allentown, Pennsylvania, Estados Unidos, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Allentown, Pennsylvania, Estados Unidos, 18104
        • Saint Luke's Cancer Center - Allentown
      • Bethlehem, Pennsylvania, Estados Unidos, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Bethlehem, Pennsylvania, Estados Unidos, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Easton, Pennsylvania, Estados Unidos, 18045
        • Saint Luke's Hospital-Anderson Campus
      • Erie, Pennsylvania, Estados Unidos, 16544
        • Saint Vincent Hospital
      • Harrisburg, Pennsylvania, Estados Unidos, 17109
        • UPMC Pinnacle Cancer Center/Community Osteopathic Campus
      • Jefferson Hills, Pennsylvania, Estados Unidos, 15025
        • Jefferson Hospital
      • Monroeville, Pennsylvania, Estados Unidos, 15146
        • Forbes Hospital
      • Natrona Heights, Pennsylvania, Estados Unidos, 15065
        • Allegheny Valley Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • West Penn Hospital
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
      • Quakertown, Pennsylvania, Estados Unidos, 18951
        • Saint Luke's Hospital-Quakertown Campus
      • West Reading, Pennsylvania, Estados Unidos, 19611
        • Reading Hospital
      • Wexford, Pennsylvania, Estados Unidos, 15090
        • Wexford Health and Wellness Pavilion
      • Willow Grove, Pennsylvania, Estados Unidos, 19090
        • Asplundh Cancer Pavilion
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
        • AnMed Health Cancer Center
      • Beaufort, South Carolina, Estados Unidos, 29902
        • Beaufort Memorial Hospital
      • Boiling Springs, South Carolina, Estados Unidos, 29316
        • Prisma Health Cancer Institute - Spartanburg
      • Easley, South Carolina, Estados Unidos, 29640
        • Prisma Health Cancer Institute - Easley
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Cancer Institute - Faris
      • Greenville, South Carolina, Estados Unidos, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29615
        • Prisma Health Cancer Institute - Eastside
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Cancer Institute - Butternut
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
      • Greer, South Carolina, Estados Unidos, 29650
        • Prisma Health Cancer Institute - Greer
      • Seneca, South Carolina, Estados Unidos, 29672
        • Prisma Health Cancer Institute - Seneca
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Medical Center
    • South Dakota
      • Aberdeen, South Dakota, Estados Unidos, 57401
        • Avera Cancer Institute-Aberdeen
      • Sioux Falls, South Dakota, Estados Unidos, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Estados Unidos, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Estados Unidos, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Bristol, Tennessee, Estados Unidos, 37620
        • Bristol Regional Medical Center
      • Collierville, Tennessee, Estados Unidos, 38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Cookeville, Tennessee, Estados Unidos, 38501
        • Cookeville Regional Medical Center
      • Johnson City, Tennessee, Estados Unidos, 37604
        • Wellmont Medical Associates Oncology and Hematology-Johnson City
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Ballad Health Cancer Care - Kingsport
      • Kingsport, Tennessee, Estados Unidos, 37660
        • Wellmont Holston Valley Hospital and Medical Center
      • Memphis, Tennessee, Estados Unidos, 38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Texas
      • Amarillo, Texas, Estados Unidos, 79106
        • The Don and Sybil Harrington Cancer Center
      • Beaumont, Texas, Estados Unidos, 77701
        • Baptist Hospitals of Southeast Texas Cancer Center
      • Conroe, Texas, Estados Unidos, 77384
        • UT MD Anderson - The Woodlands
      • Dallas, Texas, Estados Unidos, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Edinburg, Texas, Estados Unidos, 78539
        • STCC at DHR Health Institute for Research and Development
      • Houston, Texas, Estados Unidos, 77026-1967
        • Lyndon Baines Johnson General Hospital
      • Houston, Texas, Estados Unidos, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Estados Unidos, 77079
        • UT MD Anderson - West Houston
      • League City, Texas, Estados Unidos, 77573
        • UT MD Anderson - League City
      • Port Arthur, Texas, Estados Unidos, 77642
        • Baptist Regional Cancer Network-Cancer Center of Southeast Texas
      • Sugar Land, Texas, Estados Unidos, 77478
        • UT MD Anderson - Sugar Land
      • Temple, Texas, Estados Unidos, 76508
        • Scott and White Memorial Hospital
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Huntsman Cancer Institute/University of Utah
    • Vermont
      • Saint Johnsbury, Vermont, Estados Unidos, 05819
        • Dartmouth Cancer Center - North
    • Virginia
      • Bristol, Virginia, Estados Unidos, 24201
        • Ballad Health Cancer Care - Bristol
      • Burke, Virginia, Estados Unidos, 22015
        • Kaiser Permanente-Burke Medical Center
      • Fishersville, Virginia, Estados Unidos, 22939
        • Augusta Health Center for Cancer and Blood Disorders
      • Lynchburg, Virginia, Estados Unidos, 24501
        • Centra Alan B Pearson Regional Cancer Center
      • McLean, Virginia, Estados Unidos, 22102
        • Kaiser Permanente Tysons Corner Medical Center
      • Norton, Virginia, Estados Unidos, 24273
        • Ballad Health Cancer Care - Norton
      • Richmond, Virginia, Estados Unidos, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Estados Unidos, 23229
        • Virginia Cancer Institute
      • Richmond, Virginia, Estados Unidos, 23298
        • VCU Massey Comprehensive Cancer Center
      • South Hill, Virginia, Estados Unidos, 23970
        • VCU Community Memorial Health Center
      • Woodbridge, Virginia, Estados Unidos, 22192
        • Kaiser Permanente-Caton Hill Medical Center
    • Washington
      • Edmonds, Washington, Estados Unidos, 98026
        • Swedish Cancer Institute-Edmonds
      • Issaquah, Washington, Estados Unidos, 98029
        • Swedish Cancer Institute-Issaquah
      • Port Townsend, Washington, Estados Unidos, 98368
        • Jefferson Healthcare
      • Seattle, Washington, Estados Unidos, 98122
        • Swedish Medical Center-First Hill
      • Spokane, Washington, Estados Unidos, 99204
        • MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
      • Spokane, Washington, Estados Unidos, 99218
        • MultiCare Deaconess Cancer and Blood Specialty Center - North
    • West Virginia
      • Charleston, West Virginia, Estados Unidos, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
      • Morgantown, West Virginia, Estados Unidos, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, Estados Unidos, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Antigo, Wisconsin, Estados Unidos, 54409
        • Aspirus Cancer Care-Antigo-Volm Cancer Center
      • Appleton, Wisconsin, Estados Unidos, 54911
        • ThedaCare Regional Cancer Center
      • Appleton, Wisconsin, Estados Unidos, 54915
        • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
      • Ashland, Wisconsin, Estados Unidos, 54806
        • Duluth Clinic Ashland
      • Brookfield, Wisconsin, Estados Unidos, 53045
        • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
      • Eau Claire, Wisconsin, Estados Unidos, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Franklin, Wisconsin, Estados Unidos, 53132
        • Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
      • Green Bay, Wisconsin, Estados Unidos, 54301
        • Bellin Memorial Hospital
      • Janesville, Wisconsin, Estados Unidos, 53548
        • Mercyhealth Hospital and Cancer Center - Janesville
      • Johnson Creek, Wisconsin, Estados Unidos, 53038
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Estados Unidos, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Madison, Wisconsin, Estados Unidos, 53718
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marshfield, Wisconsin, Estados Unidos, 54449
        • Marshfield Medical Center-Marshfield
      • Medford, Wisconsin, Estados Unidos, 54451
        • Aspirus Medford Hospital
      • Minocqua, Wisconsin, Estados Unidos, 54548
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, Estados Unidos, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Estados Unidos, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Estados Unidos, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oshkosh, Wisconsin, Estados Unidos, 54904
        • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
      • Racine, Wisconsin, Estados Unidos, 53405
        • Ascension All Saints Hospital-Spring Street-Racine
      • Rhinelander, Wisconsin, Estados Unidos, 54501
        • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
      • Rice Lake, Wisconsin, Estados Unidos, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, Estados Unidos, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Waukesha, Wisconsin, Estados Unidos, 53188
        • UW Cancer Center at ProHealth Care
      • Waukesha, Wisconsin, Estados Unidos, 53188
        • ProHealth Waukesha Memorial Hospital
      • Wausau, Wisconsin, Estados Unidos, 54401
        • Aspirus Cancer Care-Wausau
      • Wauwatosa, Wisconsin, Estados Unidos, 53226
        • Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
      • Weston, Wisconsin, Estados Unidos, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
        • Aspirus Cancer Care - Wisconsin Rapids
    • Wyoming
      • Cheyenne, Wyoming, Estados Unidos, 82001
        • Cheyenne Regional Medical Center-West
      • Cody, Wyoming, Estados Unidos, 82414
        • Billings Clinic-Cody

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines

  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

  • Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial

  • Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible

  • Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1

  • No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass

  • Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)

  • Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)

  • Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)

  • Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)

  • Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)

  • A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:

    • The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
    • A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
    • Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
  • International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results

  • Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

  • Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period

Exclusion Criteria:

  • Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin

  • Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria

  • Documented New York Heart Association (NYHA) class III or IV congestive heart failure

  • Serious or non-healing wound, skin ulcer, or bone fracture

  • History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high

  • Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin

  • Known DPD (dihydro pyrimidine dehydrogenase) deficiency

  • Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)

  • Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization

  • History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening

  • Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:

    • Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
    • No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
    • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,

    • Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
  • History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible

    • Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible

    • Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  • Patients with known active tuberculosis (TB) are excluded

  • Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

  • Signs or symptoms of infection within 14 days prior to randomization

  • Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible

  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study

  • The administration of a live, attenuated vaccine within 28 days prior to randomization

  • Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Arm I (bevacizumab, mFOLFOX6)

Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL)

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given IV

Otros nombres:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anticuerpo monoclonal humanizado anti-VEGF
  • Anticuerpo monoclonal anti-VEGF SIBP04
  • RhuMAb anti-VEGF
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • Biosimilar BP102
  • HD204
  • Inmunoglobulina G1 (factor de crecimiento endotelial vascular anti-humano de cadena gamma de rhuMab-VEGF monoclonal de ratón humano), disulfuro con cadena ligera de rhuMab-VEGF monoclonal de ratón humano, dímero
  • Mvasi
  • MYL-1402O
  • Anticuerpo monoclonal anti-VEGF humanizado recombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • TC P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavás
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Otros nombres:
  • 5-fluracilo
  • Fluracilo
  • 5 fluorouracilo
  • 5 FU
  • 5-fluoro-2,4(1H, 3H)-pirimidindiona
  • 5-fluorouracilo
  • 5-fu
  • 5FU
  • AccuSite
  • Carac
  • Fluorouracilo
  • Fluoracilo
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Ancillary studies

Undergo collection of blood samples

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • 1-OHP
  • Dacotín
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diaminociclohexano Oxalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • JM 83
  • JM83
  • RP54780
  • SR 96669

Undergo CT or CT/PET

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Given IV

Otros nombres:
  • Ácido folínico

Undergo CT/PET

Otros nombres:
  • Imágenes médicas, tomografía por emisión de positrones
  • MASCOTA
  • Escaneo de mascotas
  • Tomografía por emisión de positrones
  • Tomografía de emisión de positrones
  • PT
  • Tomografía por emisión de positrones (procedimiento)
Experimental: Arm II (atezolizumab)

Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Ancillary studies

Undergo collection of blood samples

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Undergo CT or CT/PET

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo CT/PET

Otros nombres:
  • Imágenes médicas, tomografía por emisión de positrones
  • MASCOTA
  • Escaneo de mascotas
  • Tomografía por emisión de positrones
  • Tomografía de emisión de positrones
  • PT
  • Tomografía por emisión de positrones (procedimiento)
Experimental: Arm III (atezolizumab, bevacizumab, mFOLFOX6)

Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given IV

Otros nombres:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anticuerpo monoclonal humanizado anti-VEGF
  • Anticuerpo monoclonal anti-VEGF SIBP04
  • RhuMAb anti-VEGF
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • Biosimilar BP102
  • HD204
  • Inmunoglobulina G1 (factor de crecimiento endotelial vascular anti-humano de cadena gamma de rhuMab-VEGF monoclonal de ratón humano), disulfuro con cadena ligera de rhuMab-VEGF monoclonal de ratón humano, dímero
  • Mvasi
  • MYL-1402O
  • Anticuerpo monoclonal anti-VEGF humanizado recombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • TC P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavás
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given IV

Otros nombres:
  • 5-fluracilo
  • Fluracilo
  • 5 fluorouracilo
  • 5 FU
  • 5-fluoro-2,4(1H, 3H)-pirimidindiona
  • 5-fluorouracilo
  • 5-fu
  • 5FU
  • AccuSite
  • Carac
  • Fluorouracilo
  • Fluoracilo
  • Flurablastina
  • Fluracedil
  • Fluril
  • Fluroblastina
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Ancillary studies

Undergo collection of blood samples

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Given IV

Otros nombres:
  • 1-OHP
  • Dacotín
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diaminociclohexano Oxalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • JM 83
  • JM83
  • RP54780
  • SR 96669

Undergo CT or CT/PET

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Given IV

Otros nombres:
  • Ácido folínico

Undergo CT/PET

Otros nombres:
  • Imágenes médicas, tomografía por emisión de positrones
  • MASCOTA
  • Escaneo de mascotas
  • Tomografía por emisión de positrones
  • Tomografía de emisión de positrones
  • PT
  • Tomografía por emisión de positrones (procedimiento)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression free survival (PFS)
Periodo de tiempo: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years

The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted.

From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Tasa de SLP
Periodo de tiempo: A los 12 meses
A los 12 meses
Overall survival (OS)
Periodo de tiempo: The time from randomization to death from any cause, assessed up to 5 years

Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

The time from randomization to death from any cause, assessed up to 5 years
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Periodo de tiempo: Up to 5 years

Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment.

Up to 5 years
Incidence of adverse events
Periodo de tiempo: Up to 30 days after last cycle

Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population.

Up to 30 days after last cycle
Disease control rate (CR + PR + stable disease [SD])
Periodo de tiempo: At 12 months

Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment.

At 12 months
Duration of overall response (CR or PR)
Periodo de tiempo: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years

Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
Duration of SD
Periodo de tiempo: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years

Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals.

From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Severity of fatigue
Periodo de tiempo: At 16 weeks

Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

At 16 weeks
Physical functioning
Periodo de tiempo: At 16 weeks

Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered.

At 16 weeks
Health utility scores
Periodo de tiempo: Up to 5 years

Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire.

Up to 5 years
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Periodo de tiempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Periodo de tiempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Efficacy dependent on the number of somatic mutations
Periodo de tiempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Efficacy in tumors with MLH1 silencing
Periodo de tiempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Periodo de tiempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years
Development of progression or relapse to treatment in cfDNA
Periodo de tiempo: Up to 5 years

Will use the ITT population.

Up to 5 years
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Periodo de tiempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years
PFS of patients with high levels of diversity
Periodo de tiempo: Up to 5 years

Compared to patients with low levels of diversity. Will use the ITT population.

Up to 5 years
Change in T-cell diversity
Periodo de tiempo: Baseline to first restaging between immunotherapy arms and the standard of care arm

Will use the ITT population.

Baseline to first restaging between immunotherapy arms and the standard of care arm
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Periodo de tiempo: Baseline up to 5 years

Will use the ITT population.

Baseline up to 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Caio Max S Rocha Lima, NRG Oncology

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de enero de 2018

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

19 de diciembre de 2016

Primero enviado que cumplió con los criterios de control de calidad

19 de diciembre de 2016

Publicado por primera vez (Estimado)

20 de diciembre de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

11 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NCI-2016-01961
  • U10CA180868 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2016-01961 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • NRG-GI004/S1610
  • NRG-GI004 (Otro identificador: CTEP)
  • NRG-GI004 (Otro identificador: NRG Oncology)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir